Postoperative Adjuvant Chemotherapy Use in Patients With Stage II/III Rectal Cancer Treated With Neoadjuvant Therapy: A National Comprehensive Cancer Network Analysis
Authors:
- Joyce C. NilandJNJoyce C. Niland
- Anna ter VeerAVAnna ter Veer
- Dana MilneDMDana Milne
- Kelli Bullard DunnKDKelli Bullard Dunn
- William E. CarsonWCWilliam E. Carson
- Paul F. EngstromPEPaul F. Engstrom
- Stephen ShibataSSStephen Shibata
- John M. SkibberJSJohn M. Skibber
- Martin R. WeiserMWMartin R. Weiser
- Deborah SchragDSDeborah Schrag
- Al B. BensonABAl B. Benson
- 1 January 2013
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 31 (1) , 30-38
Abstract
Purpose: Practice guidelines recommend that patients who receive neoadjuvant chemotherapy and radiation for locally advanced rectal cancer complete postoperative adjuvant systemic chemotherapy, irrespective of tumor downstaging. Patients and Methods: The National Comprehensive Cancer Network (NCCN) Colorectal Cancer Database tracks longitudinal care for patients treated at eight specialty cancer centers across the United States and was used to evaluate how frequently patients with rectal cancer who were treated with neoadjuvant chemotherapy also received postoperative systemic chemotherapy. Patient and tumor characteristics were examined in a multivariable logistic regression model. Results: Between September 2005 and December 2010, 2,073 patients with stage II/III rectal cancer were enrolled in the database. Of these, 1,193 patients receiving neoadjuvant chemoradiotherapy were in the analysis, including 203 patients not receiving any adjuvant chemotherapy. For those seen by a medical oncologist, the most frequent reason chemotherapy was not recommended was comorbid illness (25 of 50, 50%); the most frequent reason chemotherapy was not received even though it was recommended or discussed was patient refusal (54 of 74, 73%). After controlling for NCCN Cancer Center and clinical TNM stage in a multivariable logistic model, factors significantly associated with not receiving adjuvant chemotherapy were age, Eastern Cooperative Oncology Group performance status ≥ 1, on Medicaid or indigent compared with private insurance, complete pathologic response, presence of re-operation/wound infection, and no closure of ileostomy/colostomy. Conclusion: Even at specialty cancer centers, a sizeable minority of patients with rectal cancer treated with curative-intent neoadjuvant chemoradiotherapy do not complete postoperative chemotherapy. Strategies to facilitate the ability to complete this third and final component of curative intent treatment are necessary.Keywords
This publication has 55 references indexed in Scilit:
- Neoadjuvant Treatment Response As an Early Response Indicator for Patients With Rectal CancerJournal of Clinical Oncology, 2012
- Concept and implementation of a computer-based reminder system to increase completeness in clinical documentationInternational Journal of Medical Informatics, 2011
- Long-Term Survival and Recurrence Outcomes Following Surgery for Distal Rectal CancerAnnals of Surgical Oncology, 2010
- Review: Electronic Health Records and the Reliability and Validity of Quality Measures: A Review of the LiteratureMedical Care Research and Review, 2010
- Clinical Significance of Acellular Mucin in Rectal Adenocarcinoma Patients With a Pathologic Complete Response to Preoperative ChemoradiationAnnals of Surgery, 2010
- The Time Needed for Clinical Documentation versus Direct Patient CareMethods of Information in Medicine, 2009
- Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203Journal of Clinical Oncology, 2006
- A Pooled Analysis of Adjuvant Chemotherapy for Resected Colon Cancer in Elderly PatientsNew England Journal of Medicine, 2001
- Randomized study of postoperative chemotherapy (CT) after preoperative chemoradiation (CTRT) in locally advanced rectal cancer (LARC). Preliminary resultsEuropean Journal of Cancer, 2001
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987